Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 6/20 | 0.37 |
| ▸ | HTR2C | P28335 | 6/20 | 0.37 |
| ▸ | HRH1 | P35367 | 4/20 | 0.37 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1411892 | 1.00 | DRD2 (0.47) | DRD2DRD3CYP3A4MAOAMAOB | |
| SCHEMBL1249193 | 1.00 | DRD2 (0.47) | DRD2DRD3CYP3A4MAOAMAOB | |
| SCHEMBL29364314 | 1.00 | DRD2 (0.47) | DRD2DRD3CYP3A4MAOAMAOB | |
| SCHEMBL12891390 | 0.84 | MAPT (0.47) | DRD2DRD3CYP3A4MAOAMAOB | |
| SCHEMBL232991 | 0.84 | CYP3A4 (0.68) | CYP3A4MAOAMAOBMAPTMAPK1 | |
| SCHEMBL12810063 | 0.80 | MAPT (0.70) | DRD2DRD3CYP3A4MAOAMAOB | |
| SCHEMBL13825739 | 0.78 | DRD2 (0.53) | DRD2DRD3CYP3A4LTB4RLTB4R2 | |
| SCHEMBL8228508 | 0.78 | DRD2 (0.53) | DRD2DRD3CYP3A4LTB4RLTB4R2 | |
| SCHEMBL8231800 | 0.78 | DRD2 (0.53) | DRD2DRD3CYP3A4LTB4RLTB4R2 | |
| SCHEMBL8232785 | 0.78 | DRD2 (0.53) | DRD2DRD3CYP3A4LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633203-B2 | Use of pterocarpans as active anti-cellulite ingredients | SYMRISE AG (DE) | 2014-01-21 | — | — | US | disclosed |
| US-20110034486-A1 | USE OF PTEROCARPANS AS ACTIVE ANTI-CELLULITE INGREDIENTS | SYMRISE GMBH & CO., KG (DE) | 2011-02-10 | — | — | US | disclosed |
| US-5399558-A | Isoflavonoid antibacterial compounds, compositions and use | PATHOGENESIS CORPORATION (US) | 1995-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034486-A1 | USE OF PTEROCARPANS AS ACTIVE ANTI-CELLULITE INGREDIENTS | FABP4, PLIN1, CPT1B | DRD2 1349/4885DRD3 796/4885CYP3A4 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.